MedWatch

Bank manager: A change towards foreign venture capital, however…

In recent years Henrik Specht, business account manager in Danske Bank, has noticed a shift towards foreign venture capital in the biotech industry, but the Danes could yet be making a comeback.

There is widespread consensus in the biotech industry that capital is extremely hard to come by these days. An issue that business account manager Henrik Specht is also faced with, when he sits down with the biotech companies, whose bank accounts he manages.

“Many companies have had to pack it in during the start-up phase. But at the moment, when I meet with the many biotech clients, I actually sense a certain optimism and believe that they can succeed in securing capital, also going forward,” he says, adding:

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier